2026
An efficient purification process for adeno-associated viral vectors (AAVs) is essential for the success of new drugs during the investigational phase and throughout the product development lifecycle. Optimizing the AAV purification process early on can significantly reduce costs for clients and patients once large-scale production is established. This presentation will discuss a screening method for separating empty and full AAVs using three different CIM QA HR formats and how to scale this method for large-scale production.
Key learning objectives:
- Understanding the superiority of monoliths for purifying large biomolecules.
- Exploring the use of different CIM monolithic plates in AAV process development.
- Achieving high reproducibility across various product families and purification scales with the CIM QA HR line.
- Guiding the selection of an appropriate CIM QA HR monolith product for screening based on specific laboratory needs and available equipment.
Speakers:
Marko Narobe, Product Manager for High-Throughput Solutions at Sartorius BIA Separations
Marko is a molecular biologist. He joined Sartorius BIA Separations in 2020 as a Technical Support Professional. During his carrer he gained deep technical understanding of monolithic chromatography, and clients’ needs. As a Product Manager he covers Sartorius BIA Separations’ high throughput solutions.
Sara Drmota Prebil, PhD, Process Development Manager at Sartorius BIA Separations
Dr. Sara Drmota Prebil is a Process Development Manager for Viral Vectors and Vaccines at Sartorius BIA Separations, specializing in downstream bioprocess development and purification. With a PhD in Chemical Sciences and a Biochemistry degree from the University of Ljubljana, she leads projects to create application-ready downstream processes for viral vectors.
Nicholas Pearman, PhD, Senior Scientist at Pharmaron Biologics UK Ltd
Nick is a scientist with over ten years of experience in viral vaccine manufacturing and AAV gene therapy. He holds a BSc, MSc, and PhD in related fields, contributing to CMC development with a focus on biologics optimization. Skilled in high throughput development and automation, Nick is an innovator in biopharmaceutical R&D, advancing therapeutic platforms to clinical readiness.
